A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)
Active, not recruiting · Phase 3 · NCT06730061
Conditions: Primary Biliary Cholangitis
At a glance
- Research payments reported, 2025
- $2,575
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 18
About the trial
- Sponsor
- Ipsen
- Tested
- Elafibranor (drug)
- Dates
- Started 2025-01-16; completion 2032-04-08
- Results posted
- Not yet
The purpose of this study is to find out about the safety and how well the study intervention (elafibranor) works in participants with PBC. The participants in this study will have confirmed PBC with inadequate response or intolerance to UDCA, which is a medication used in the management and treatment of cholestatic liver disease. PBC is a slowly progressive disease characterised by damage of the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many patients with PBC may require a liver transplant or may die if the disease progresses and a l…
From ClinicalTrials.gov, last updated 2026-10-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Bioscience Inc. reported $2,575 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $2,575
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.